MX2016005428A - Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt. - Google Patents

Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.

Info

Publication number
MX2016005428A
MX2016005428A MX2016005428A MX2016005428A MX2016005428A MX 2016005428 A MX2016005428 A MX 2016005428A MX 2016005428 A MX2016005428 A MX 2016005428A MX 2016005428 A MX2016005428 A MX 2016005428A MX 2016005428 A MX2016005428 A MX 2016005428A
Authority
MX
Mexico
Prior art keywords
glucopyranosyl
urea derivatives
substituted indole
sglt inhibitors
sglt
Prior art date
Application number
MX2016005428A
Other languages
English (en)
Inventor
Fields Todd
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016005428A publication Critical patent/MX2016005428A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044Pyrrole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto de Fórmula I; o una sal farmacéuticamente aceptable del mismo.
MX2016005428A 2013-11-01 2014-10-28 Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt. MX2016005428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898494P 2013-11-01 2013-11-01
PCT/US2014/062548 WO2015065956A1 (en) 2013-11-01 2014-10-28 Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors

Publications (1)

Publication Number Publication Date
MX2016005428A true MX2016005428A (es) 2016-08-11

Family

ID=51862614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005428A MX2016005428A (es) 2013-11-01 2014-10-28 Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.

Country Status (39)

Country Link
US (1) US9145437B2 (es)
EP (1) EP3063162B1 (es)
JP (1) JP6147429B2 (es)
KR (1) KR101838826B1 (es)
CN (1) CN105636972B (es)
AP (1) AP2016009137A0 (es)
AR (1) AR098134A1 (es)
AU (1) AU2014342612B2 (es)
BR (1) BR112016008704B1 (es)
CA (1) CA2924516C (es)
CL (1) CL2016000988A1 (es)
CR (1) CR20160146A (es)
CY (1) CY1119540T1 (es)
DK (1) DK3063162T3 (es)
DO (1) DOP2016000062A (es)
EA (1) EA029516B1 (es)
ES (1) ES2646125T3 (es)
HK (1) HK1222661A1 (es)
HR (1) HRP20171514T1 (es)
HU (1) HUE034689T2 (es)
IL (1) IL244896B (es)
JO (1) JO3298B1 (es)
LT (1) LT3063162T (es)
MA (1) MA38991B1 (es)
ME (1) ME02839B (es)
MX (1) MX2016005428A (es)
NO (1) NO3099623T3 (es)
NZ (1) NZ717880A (es)
PE (1) PE20160663A1 (es)
PH (1) PH12016500809B1 (es)
PL (1) PL3063162T3 (es)
PT (1) PT3063162T (es)
RS (1) RS56417B1 (es)
SG (1) SG11201602950UA (es)
SI (1) SI3063162T1 (es)
TN (1) TN2016000125A1 (es)
TW (1) TWI657093B (es)
UA (1) UA117137C2 (es)
WO (1) WO2015065956A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128493B (zh) * 2018-02-08 2021-01-12 亚宝药业集团股份有限公司 吡喃糖取代杂环化合物的盐及其制备方法和用途
WO2024055932A1 (zh) * 2022-09-13 2024-03-21 亚宝药业集团股份有限公司 氮杂环化合物、其药物组合物和用于预防和/或治疗疾病的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200501094B (en) * 2002-08-08 2006-10-25 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
CN100413878C (zh) * 2002-08-23 2008-08-27 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
CA2581922A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
CA2588963C (en) 2004-11-18 2013-06-25 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) * 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物

Also Published As

Publication number Publication date
IL244896B (en) 2019-02-28
DOP2016000062A (es) 2016-03-31
MA38991B1 (fr) 2018-09-28
RS56417B1 (sr) 2018-01-31
EP3063162B1 (en) 2017-08-16
PE20160663A1 (es) 2016-07-09
CN105636972A (zh) 2016-06-01
CA2924516A1 (en) 2015-05-07
JO3298B1 (ar) 2018-09-16
PT3063162T (pt) 2017-11-14
HK1222661A1 (zh) 2017-07-07
PH12016500809A1 (en) 2016-06-13
BR112016008704B1 (pt) 2022-11-29
CA2924516C (en) 2019-09-10
BR112016008704A8 (pt) 2020-03-17
ES2646125T3 (es) 2017-12-12
SG11201602950UA (en) 2016-05-30
CY1119540T1 (el) 2018-03-07
KR101838826B1 (ko) 2018-03-14
US20150126469A1 (en) 2015-05-07
CN105636972B (zh) 2018-05-22
SI3063162T1 (sl) 2017-10-30
DK3063162T3 (en) 2017-10-02
NO3099623T3 (es) 2018-04-21
JP2016535032A (ja) 2016-11-10
EA201690593A1 (ru) 2016-08-31
US9145437B2 (en) 2015-09-29
TN2016000125A1 (en) 2017-10-06
UA117137C2 (uk) 2018-06-25
HRP20171514T1 (hr) 2017-11-17
EA029516B1 (ru) 2018-04-30
AP2016009137A0 (en) 2016-04-30
PH12016500809B1 (en) 2016-06-13
HUE034689T2 (hu) 2018-02-28
AU2014342612A1 (en) 2016-03-31
PL3063162T3 (pl) 2018-01-31
JP6147429B2 (ja) 2017-06-14
WO2015065956A1 (en) 2015-05-07
AU2014342612B2 (en) 2016-09-29
CL2016000988A1 (es) 2016-11-11
CR20160146A (es) 2016-05-30
TWI657093B (zh) 2019-04-21
EP3063162A1 (en) 2016-09-07
IL244896A0 (en) 2016-05-31
TW201609784A (zh) 2016-03-16
KR20160060138A (ko) 2016-05-27
ME02839B (me) 2018-01-20
MA38991A1 (fr) 2017-11-30
NZ717880A (en) 2017-12-22
LT3063162T (lt) 2017-10-25
AR098134A1 (es) 2016-05-04

Similar Documents

Publication Publication Date Title
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
IN2014DN10670A (es)
JO3318B1 (ar) مثبطات bace
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
PH12018501709A1 (en) Naphthridinedione derivatives
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12016500809A1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
EA201690749A1 (ru) Новые ингибиторы sglt1
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration